Related Experiment Video

Updated: May 19, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
05:35

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level

Published on: January 19, 2024

Pediatric hemoglobinopathies: from the bench to the bedside

Tonya A Schneidereith1

  • 1Stevenson University, MD, USA.

Annual Review of Nursing Research
|August 16, 2012
PubMed

Insights

Beta-chain hemoglobinopathies like sickle cell disease (SCD) and beta-thalassemia are common genetic disorders. Understanding fetal hemoglobin (HbF) regulation and genetic factors is key to improving patient care and treatment outcomes.

Area of Science:

  • Genetics
  • Hematology
  • Molecular Biology

Background:

  • Beta-chain hemoglobinopathies, including sickle cell disease (SCD) and beta-thalassemia, are prevalent genetic disorders affecting the beta-globin gene.
  • These conditions result from mutations leading to diverse clinical manifestations and severity.
  • Fetal hemoglobin (HbF) plays a crucial role in alleviating disease symptoms, making its regulation a significant research focus.

Purpose of the Study:

  • To review the genomics of hemoglobinopathies, encompassing pathophysiology, HbF regulation, and genetic factors.
  • To explore current pharmacologic and non-pharmacologic therapies for these conditions.
  • To provide insights relevant to caregivers, including physical and psychological sequelae, genetic counseling, and educational impacts on children.

Main Methods:

  • Review of existing literature on hemoglobinopathies, focusing on genetic mechanisms and therapeutic strategies.
  • Analysis of research on the regulation of fetal hemoglobin (HbF), including quantitative trait loci (QTLs) and single nucleotide polymorphisms (SNPs).
  • Compilation of studies on clinical management, patient care, and the impact on children and families.

Main Results:

  • Identified key genetic factors, including QTLs and SNPs, influencing HbF levels and disease severity.
  • Summarized current therapeutic approaches, highlighting both pharmacologic and non-pharmacologic interventions.
  • Detailed the physical and psychological sequelae associated with hemoglobinopathies in children, emphasizing the need for comprehensive care.

Conclusions:

  • A thorough understanding of hemoglobin physiology, pathophysiology, and genetic underpinnings is essential for effective management.
  • Advances in understanding HbF regulation offer potential therapeutic targets for alleviating symptoms.
  • Nurses and caregivers equipped with this knowledge can significantly improve the quality of life for children and families affected by hemoglobinopathies.

More Related Videos

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Gene Families01:57

Gene Families

Gene families consist of groups of genes proposed to have originated from a common ancestor. Typically these arise through events in which a gene or genes are mistakenly duplicated during cell division. Unlike their parent genes (which are subject to selection pressure to maintain function), these gene copies do not need to preserve their sequences and may evolve at a relatively faster rate.
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Hemoglobin01:24

Hemoglobin

Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...